By Fineline Cube 
China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) and its US partner Instil Bio Inc (NASDAQ: TIL) announced multiple clinical updates and plans for their IMM2510/AXN-2510, a bispecific antibody targeting PD-L1 and VEGF, for the treatment of non-small cell lung cancer (NSCLC).
Clinical Data and Studies
Early clinical data showed that IMM2510/AXN-2510 delivered a 23% overall response rate (ORR) in 23 patients with recurrent/refractory NSCLC. A Phase II study evaluating IMM2510/AXN-2510 in combination with chemotherapy for first-line NSCLC has commenced patient enrollment. Furthermore, a Phase III study for the combination of IMM2510/AXN-2510 and chemotherapy in first-line NSCLC is planned to start in mid-2026 in China.
Licensing Agreement
Instil Bio entered into a USD 2 billion licensing agreement with ImmuneOnco in August of last year. This agreement secured global development and commercialization rights to ImmuneOnco’s IMM2510 and IMM27M, excluding Greater China.-Fineline Info & Tech